GlassScriptPhysician profile
Sneha Mathew
NPI 1467962787
$4,540.42
in general payments reported to CMS, 2019-2025
33 companies · $862 in 2025
The $862 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $814 · 2022: $1,044 · 2023: $759 · 2024: $1,061 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,172.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $546.74 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $306.96 | 2021-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $283.10 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $239.70 | 2021-2025 | |
| Abbott Laboratories | $209.72 | 2023-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $209.68 | 2021-2023 | |
| Exact Sciences Corporation | $193.49 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $183.42 | 2022-2023 | |
| Abbvie INC. | $114.82 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.44 | 2021-2024 | Jardiance |
| Amgen INC. | $107.58 | 2023-2025 | Otezla, Repatha, Repatha |
| Shield Therapeutics INC | $83.51 | 2024 | |
| Idorsia Pharmaceuticals US INC | $83.45 | 2022-2024 | Quviviq |
| Esperion Therapeutics, INC. | $74.74 | 2024-2025 | Nexletol |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $73.79 | 2025 | Korlym |
| Amarin Pharma, INC. | $67.91 | 2022 | |
| Optinose US, INC. | $67.11 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $50.26 | 2021-2024 | Zoryve |
| Janssen Pharmaceuticals, INC | $44.37 | 2023-2024 | Xarelto |
| Medtronic, INC. | $42.91 | 2022-2024 | Intellis Adaptivestim |
| Eisai INC. | $42.14 | 2021 | |
| Almatica Pharma LLC | $27.87 | 2025 | Loreev Xr |
| Boston Scientific Corporation | $27.51 | 2025 | General - Therapies |
| Stryker Corporation | $23.86 | 2024 | Mako, Triathlon |
| Novartis Pharmaceuticals Corporation | $22.93 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $21.36 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.73 | 2022 | |
| Si-Bone, INC. | $19.58 | 2024 | |
| Dexcom, INC. | $18.94 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.02 | 2023 | Veozah |
| Linus Health, INC. | $16.52 | 2023 | |
| Mylan Specialty L.P. | $14.08 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.